attachment
attachment
attachment
attachment
attachment
attachment

Septate fungal keratitis treatment

Reading File
analyse_media
analyse_media
Finding Sources
Finding Sources
Searching PubMed

"fungal keratitis" AND treatment

Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from both textbooks. Let me compile the full answer.

Microscopy Findings

The images show:
  • PAS-stained preparation (pink/magenta images): Thin, uniform, septate hyphae with acute-angle (~45°) branching running in parallel bundles - morphology consistent with Aspergillus or Fusarium species
  • Wet mount (unstained image): Thin septate hyphae with occasional branching visible on direct microscopy
Diagnosis: Filamentous (septate) fungal keratitis - most likely Fusarium or Aspergillus spp.

Treatment of Septate (Filamentous) Fungal Keratitis

1. First-Line Topical Antifungals

DrugConcentrationDosing
Natamycin (drug of choice)5% dropsQ1-2h initially (around clock for 48h), then taper over weeks
Voriconazole (alternative)1-2% dropsQ1-2h, must be compounded
Econazole1%Q1-2h
Amphotericin B0.15%Q1-2h (more useful for Candida; secondary option here)
Natamycin 5% is the only FDA-approved topical antifungal for mycotic keratitis. All others require compounding.

2. Epithelial Debridement

  • Remove the epithelium over the lesion to enhance antifungal penetration - topical antifungals penetrate poorly through intact epithelium
  • Regularly debride mucus and necrotic tissue with a spatula

3. Cycloplegia

  • Cyclopentolate 1% TID, or
  • Atropine 1% BID-TID if hypopyon, fibrin, or significant anterior chamber reaction is present

4. Strict Steroid Avoidance

  • Stop all topical steroids immediately. If already on steroids, taper and discontinue rapidly. Steroids are a major predisposing factor and will worsen fungal keratitis.

5. Systemic Antifungals (for severe, deep, or limbus-threatening disease)

  • Voriconazole: 400 mg PO BID x 1 day (loading), then 200 mg PO BID
  • Itraconazole: 200 mg PO OD, reduce to 100 mg OD
  • Fluconazole: 200 mg PO BID
  • Posaconazole: 300 mg PO BID x 1 day, then 300 mg OD
Systemic agents are indicated for: deep stromal ulcers, lesions near the limbus, suspected fungal endophthalmitis.

6. Intrastromal / Intracameral Injections (refractory cases)

  • Voriconazole 50 mcg/0.1 mL intrastromal depot
  • Amphotericin B 10 mcg/0.1 mL intrastromal or intracameral
  • Useful when surface therapy is failing and culture sensitivities are known

7. Anticollagenase therapy

  • Doxycycline 100 mg BID - for its anticollagenase effect when significant corneal thinning is present

8. IOP Monitoring

  • Measure IOP regularly (Tono-Pen preferred). Treat elevated IOP if present.

9. Broad-spectrum Antibiotic Cover

  • Consider topical broad-spectrum antibiotics to prevent or treat bacterial co-infection

10. Surgical Options (medical treatment failure)

  • Superficial keratectomy - debulk the lesion
  • Therapeutic penetrating keratoplasty (TPK) - when medical therapy fails, ideally before infection reaches the limbus; include intracameral antifungal at time of surgery
  • Deep anterior lamellar keratoplasty (DALK) - consider; note anterior lamellar has higher recurrence risk
  • Anterior chamber washout + intracameral antifungal - for cases with stable corneal infiltrate but enlarging endothelial exudation

Follow-Up

  • Daily review initially
  • Response is much slower than bacterial keratitis - weeks to months of treatment expected
  • Stability (not necessarily improvement) after starting treatment is a favorable sign
  • Epithelial healing alone does NOT confirm treatment success - fungus can still be active in deep stroma
  • Hospital admission may be needed for compliance

Sources: Kanski's Clinical Ophthalmology (10th ed.), pp. 233-234 | Wills Eye Manual, pp. 210-212
Recent evidence note (PubMed 2025): A systematic review on corneal cross-linking (PMID 40269767) and a meta-analysis on photoactivated CXL (PMID 37951953) suggest adjunctive corneal collagen cross-linking (CXL) may accelerate healing in fungal keratitis - this is an emerging adjunct therapy not yet in standard textbooks, worth considering in refractory cases.

Can ointment moxifloxacin be used?

Finding Sources
Searching PubMed

moxifloxacin AND "fungal keratitis"

Searching the Web

moxifloxacin antifungal activity keratitis fluoroquinolone fungal

Reading Article

PMID: 18952649

Reading Article

PMID: 28306602

Here is a clear, evidence-based answer:

Can Moxifloxacin Ointment Be Used in Septate Fungal Keratitis?

Short answer: Not as primary/sole treatment. Drops may serve a limited adjunctive role; ointment has no established role.


Why Moxifloxacin Is NOT an Antifungal

Moxifloxacin is a 4th-generation fluoroquinolone that targets bacterial DNA gyrase and topoisomerase IV. It has no primary antifungal indication and is not listed in any guideline as treatment for fungal keratitis.
Ointment formulations specifically are also problematic in active keratitis because:
  • They reduce drug bioavailability at the stromal level compared to drops
  • They can trap organisms under a film at the corneal surface
  • The base (petrolatum/mineral oil) does not aid antifungal penetration

What the Evidence Actually Shows (About Drops, Not Ointment)

StudyFinding
Day et al., Br J Ophthalmol 2009 (PMID 18952649)Moxifloxacin showed in vitro activity against Fusarium but NOT Aspergillus. MICs were much higher than standard antifungals (natamycin, voriconazole, amphotericin B)
Matoba et al., Cornea 2017 (PMID 28306602)11 culture-proven fungal keratitis patients treated initially with moxifloxacin 0.3% drops - only 2/11 (18%) resolved; both were Curvularia and Alternaria (dematiaceous fungi), not Fusarium or Aspergillus

Key points from evidence:

  • Any activity is only demonstrated for moxifloxacin drops (0.3-0.5%), not ointment
  • Activity against Fusarium is modest at best; none against Aspergillus
  • The mechanism is likely inhibition of fungal topoisomerase II at very high concentrations - but achievable corneal levels are insufficient compared to dedicated antifungals
  • It may explain why some fungal ulcers appear to "improve" when initially treated empirically as bacterial before the diagnosis is confirmed

What to Do in Your Case

Based on the microscopy images (septate hyphae, acute-angle branching - likely Fusarium or Aspergillus):
  1. Do NOT use moxifloxacin ointment as antifungal treatment - it will not work
  2. Start Natamycin 5% drops Q1-2h immediately (first-line for filamentous/septate fungi)
  3. Add Voriconazole 1% drops (compounded) if response is poor
  4. Moxifloxacin drops may be kept as a co-prescription solely to prevent bacterial superinfection - but this is the only justifiable role
  5. Stop steroids if on any
The bottom line: moxifloxacin ointment has no role here. The antifungal treatment protocol from the previous answer should be followed.
This is a shared conversation. Sign in to Orris to start your own chat.